Business Context and Reporting Period
Veracyte, Inc. (VCYT) filed a Form 8-K on January 11, 2026, to announce preliminary, unaudited estimated financial and operating results for the fourth quarter and full year ended December 31, 2025. The company is a Delaware corporation headquartered in South San Francisco, California.
Key Financial Metrics
Fourth Quarter 2025 (Preliminary Estimates)
- Total Revenue: $138 million to $140 million
- Testing Revenue: $134 million to $136 million
- Testing Volume: Approximately 45,500 tests
Full Year 2025 (Preliminary Estimates)
- Total Revenue: $515 million to $517 million
- Testing Revenue: $491 million to $493 million
- Testing Volume: Approximately 169,700 tests
- Adjusted EBITDA Margin: Greater than 25%
Net Income Margin: The filing states that an estimate for net income margin is not available without unreasonable effort due to the unavailability of reliable estimates for stock-based compensation and other adjustments.
Cash Flow, Debt, and Liquidity: The filing text does not provide specific values for cash flow, debt levels, or liquidity metrics.
Material Changes and Comparisons
The filing provides preliminary estimates for the 2025 period but does not include specific comparative figures for the prior year (2024) or year-over-year percentage changes within the text provided.
Outlook, Risks, and Unusual Items
- Unaudited Status: All reported figures are preliminary and unaudited. They are subject to completion of financial closing procedures and audit adjustments, which may result in material differences from final audited results.
- Reconciliation Limitations: Management cannot currently provide a reconciliation of adjusted EBITDA to net income due to the unavailability of reliable estimates for certain components, including stock-based compensation and acquisition-related expenses.
- Legal Disclaimer: The information furnished is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the final audited financial statements for the full year ended December 31, 2025, once released, to confirm if actual results fall within the preliminary ranges.
- Review the upcoming 10-K filing for the reconciliation of adjusted EBITDA to net income and specific details on stock-based compensation and acquisition-related expenses.
- Confirm the final testing volume and revenue mix between testing and other revenue streams.
- Monitor for any material adjustments to the preliminary estimates resulting from the audit process.